GLP-1 & Vision Loss: Do Drugs Like Wegovy and Zepbound Cause Vision Changes?

Many patients describe weight-loss medications such as Wegovy, Zepbound, and Ozempic as life-changing, but some have raised concerns about potential serious side effects. Recently, GLP-1 companies have been facing lawsuits alleging that these medications may be associated with a condition potentially causing vision loss in some patients.

As demand for medically supported weight-loss programs continues to grow, the potential link between GLP-1s and vision loss is under considerable scrutiny. This guide explores the lawsuits surrounding the alleged vision-related side effects of brand-name GLP-1 drugs, the existing evidence, and why choosing a reliable, expert-guided program is critical for safe and sustainable weight loss.

Before examining the lawsuits, it helps to understand the main eye condition at the center of these claims: NAION.

What is NAION, and Is It Caused by GLP-1s?

Non-arteritic anterior ischemic optic neuropathy (NAION) is an ophthalmological condition, recognized as the leading cause of acute optic nerve injury. The condition is more likely to develop in individuals older than 50, regardless of gender. However, the American Academy of Ophthalmology (AAO) says that the exact pathogenesis and effective treatments for this disease are yet to be established.

NAION includes sudden, painless vision loss, usually affecting one eye, though bilateral vision impairment is possible in rare cases. Risk factors for developing this condition include diabetes, smoking, and hypertension, but more research is necessary to determine the exact contributors.

In a separate study, the AAO recognizes a “possible small increased risk of NAION” in patients using semaglutide. However, it describes the risk as “low and yet to be confirmed,” further suggesting the research gaps in assessing the exact role of GLP-1s in the development of NAION. For now, available evidence points to a potential association in some cases but doesn’t establish that GLP-1 medications directly cause the condition.

Another study that recognized an increased risk of developing NAION after five years of GLP-1 use in type 2 diabetes patients highlights the inconclusive relationship between the condition and the medication. As with other sources, this study underscores the need for further research before concrete conclusions can be drawn.

How the Connection Between NAION and GLP-1s Is Perceived Globally

While the U.S. doesn’t yet require manufacturers to include a NAION-specific warning on GLP-1 medication labels, the situation differs slightly in other parts of the world:

• European Union: The European Medicines Agency recommended manufacturers list NAION as a very rare side effect of semaglutide medications, including Ozempic, Rybelsus, and Wegovy
• Australia: As of July 2026, product information for GLP-1 medications marketed in Australia, including Trulicity, Ozempic, Wegovy, Mounjaro, and Saxenda, lists NAION as a rare but serious eye condition that may cause permanent vision loss
• Canada: The current Ozempic product monograph issued by Novo Nordisk Canada lists an increased risk of NAION development during semaglutide treatment as one of the rare ophthalmological side effects

GLP-1 Vision Loss Lawsuits: What Are the Key Allegations?

A series of lawsuits has brought the potential association between GLP-1s and eyesight into the public eye. Some companies have issued official statements addressing the allegations, while others have chosen not to discuss the ongoing litigation process publicly. Still, growing awareness of these lawsuits brings scrutiny and skepticism over the overall safety of weight-loss medications.

The following sections explore two ongoing lawsuits concerning GLP-1 and vision changes, including the plaintiffs’ allegations, the medications involved, and any conclusions established in the litigation to date.

1. GLP-1 Vision Loss NAION Lawsuit: Eastern District of Pennsylvania

In December 2025, lawsuits alleging the development of NAION following the use of GLP-1 medication were consolidated under MDL No. 3163. The Judicial Panel consolidated 21 actions pending across three districts under a single umbrella, centralizing them in the Eastern District of Pennsylvania.

The subject of the litigation is the plaintiffs’ claim that their use of GLP-1 receptor antagonists, including Ozempic, Wegovy, Saxenda, and Trulicity, caused them to develop NAION. These medications are manufactured by Eli Lilly or Novo Nordisk, well-known providers of type 2 diabetes and weight-loss drugs.

The consolidated cases raise questions about the medications’ development, manufacturing, testing, regulatory history, and potential to cause NAION. The plaintiffs also allege that the manufacturers failed to warn them about the potential adverse effects of this nature and magnitude.

As of July 2, 2026, the liability litigation against two manufacturers expanded, now encompassing:

• Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro, and Zepbound
• 130+ cases sharing similar claims of developing NAION after using the mentioned medications, either for type 2 diabetes and/or long-term weight management

The claims remain under review, and, aside from the rising number of cases with similar concerns, no definitive legal conclusions have been reached. While Novo Nordisk pointed to a company-funded study that found no direct connection between the medication and NAION, Eli Lilly offered no comment on the litigation, stating it was reviewing the health risk data.

2. GLP-1 Lawsuit for Vision Loss: New Jersey

Novo Nordisk isn’t facing claims only through the federal MDL in Pennsylvania. According to the Wall Street Journal, more than 90 cases have been filed in the New Jersey state court with similar claims since 2025. Allegedly, the use of Ozempic and Wegovy, manufactured by Novo Nordisk, has also led to patients being diagnosed with NAION.

In October 2025, the New Jersey Supreme Court grouped the GLP-1-related NAION lawsuits in Bergen County. However, there has been no official confirmation that Ozempic or Wegovy is the root cause of the reported vision loss from GLP-1.

Can GLP-1 Cause Vision Problems Other Than NAION?

The association between GLP-1s and eyesight seems more relevant in certain groups of patients with pre-existing health conditions. While the exact connection between GLP-1s and NAION remains under investigation, other vision-related conditions may have a clearer connection with the use of GLP-1s, including:

1. Diabetic retinopathy
2. Temporary blurred vision

1. Diabetic Retinopathy

According to a JAMA cohort study, GLP-1 use has a slight association with the development of diabetic retinopathy (DR). This eye condition, as the name itself implies, develops in patients with diabetes and is one of the most common causes of vision loss and preventable blindness in adults.

In most cases, it develops due to high blood glucose levels and deregulated glucose pathways. While the development of DR was slightly increased among patients with diabetes who used GLP-1s, fewer patients experienced serious, eyesight-threatening complications. The study concludes that treatment with GLP-1s may potentially reduce the likelihood of DR progressing to vision loss or blindness, even in patients with pre-existing DR.

2. Temporary Blurred Vision

Based on a review of ocular complications associated with GLP-1s, blurry vision may occur due to fluctuating blood sugar levels, which can cause the eye's lens to swell or shrink. The use of these medications has also been associated with dry eye disease, which, in addition to blurred vision, may contribute to general discomfort and a gritty sensation in the eyes.

The review underscores the need for additional research into potential vision loss associated with GLP-1s, particularly conditions such as NAION, worsening DR, and macular edema. It also suggests that individual factors, such as existing eye conditions, comorbidities, and structural features of the optic nerve, contribute to the overall risk.

How To Choose a Reliable Medically Supported Weight Loss Program

When starting a medically supported weight-loss program, having expert guidance can provide safety throughout treatment. While GLP-1s can be obtained through a prescription from your healthcare provider, a medically guided program can offer more structured support, especially if you’re concerned about potential side effects and impact on existing health conditions, obstacles, and the questions that may arise if and when you decide to stop using medication.

When exploring GLP-1 options and providers, consider the following:

• Eligibility assessment: Choose a provider that evaluates your medical history, existing health conditions, and individual risk factors before prescribing GLP-1 medication, including any factors that could affect your eye health
• Standards and quality requirements: Prioritize providers that are transparent about the ingredients they use and pharmacies they collaborate with. Regulatory compliance, third-party testing, and overall quality control are essential
• Expert support: Choose a platform that offers ongoing access to healthcare professionals, especially for support with dosing, side effects, and tapering off. A guided approach helps you optimize your lifestyle simultaneously
• Broader lifestyle guidance: Consider a platform that offers support beyond medication, including practical guidance on nutrition and sustainable lifestyle changes to help you maintain healthy habits during and beyond treatment

If you're considering personalized GLP-1 treatment for weight loss, Olive combines prescription treatment with tailored nutrition guidance and ongoing lifestyle optimization to help you build sustainable, healthy habits. It helps you stay on track and recognize foods and behaviors that may be preventing you from reaching your full potential.

Olive: Individual Weight Loss Protocols With Continuous Expert Support

Olive is a holistic health companion offering access to compounded weight-loss medication, with a strong emphasis on safety and quality control. Prescription treatment is available only to individuals who meet eligibility criteria following a medical assessment by a licensed clinician.

Each 503A compounding pharmacy Olive collaborates with must source its active pharmaceutical ingredients (APIs) from FDA-registered manufacturers, with every API accompanied by a valid Certificate of Analysis verifying quality and regulatory compliance. Additionally, each partner pharmacy conducts routine, rigorous third-party quality testing to assess potency, sterility, quality, and contamination in accordance with state and USP standards.

The platform brings prescribing clinicians together with physicians experienced in the nutritional aspects of metabolic health, combining nutrition and medication to build a strong foundation for sustainable results and broader lifestyle improvement.

Flagship Features of the Olive Protocol

Access to the Olive Protocol unlocks multiple features and tools in addition to prescription medication:

If you're considering GLP-1 treatment for weight loss, get Olive’s personalized medical guidance and nutrition support to help you navigate treatment with greater confidence. Take the free 5-minute intake form to check whether you’re eligible.

FAQs

Should I stop taking a GLP-1 if I experience vision changes?

Any adverse health symptoms you experience while undergoing GLP-1 treatment should be assessed promptly by a healthcare professional. If you experience vision changes, particularly sudden or rapidly worsening eyesight, contact your healthcare provider or seek urgent medical attention without delay.

Who is at greater risk of GLP-1-related vision issues?

Patients with diabetes, especially those with pre-existing eye conditions, appear to be more susceptible to vision issues while using GLP-1 medications. However, not all studies agree on this matter, and some even suggest that GLP-1 use may be associated with a lower risk of certain serious diabetic retinopathy complications.

While the scientific evidence remains mixed, it’s best to choose your provider wisely and discuss your individual risk factors with a licensed healthcare professional.

Has the Ozempic eyesight lawsuit proven any vision concerns?

No, there is no definite conclusion in the Ozempic vision loss lawsuit as the litigation is still underway. Ozempic is only one of the medications named in the consolidated cases, alongside Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro, and Zepbound. Researchers are still investigating the potential connection between these medications and conditions such as NAION, while the courts are examining the claims that manufacturers failed to warn patients about potential vision-related side effects.

Featured image source: sergey kolesnikov via Shutterstock